VR: Bridging The Employment Gap For Americans With Disabilities
Paul Toomey is the President of Geographic Solutions. He's an expert in labor market data, workforce development and unemployment insurance.
getty
Nealy one in four adults in the United States reported having a disability in 2022, according to the Centers for Disease Control. Despite representing a significant portion of the population, individuals with disabilities face disproportionate challenges in securing employment opportunities. As of April 2025, the unemployment rate for people with a disability (8.2%) was twice as high as those with no disability (3.6%), according to the Bureau of Labor Statistics (BLS).
Vocational Rehabilitation (VR) programs play a crucial, yet often overlooked, role in helping individuals with disabilities overcome barriers to employment. As the American workforce continues to evolve amid technological advancements and shifting economic landscapes, VR programs can serve as an important bridge connecting skilled workers with meaningful employment opportunities. They also offer a strategic approach to expanding labor force participation while also creating pathways to economic independence for millions of Americans with disabilities.
The Rehabilitation Act of 1973 and its subsequent amendments, including significant expansions through the Workforce Innovation and Opportunity Act (WIOA), established the framework for today's VR programs. These landmark legislations aim to empower individuals with disabilities to find gainful employment, become economically self-sufficient and contribute to their local communities and economies.
The scope of VR services is intentionally broad to address the diverse needs of individuals with physical, cognitive or mental health disabilities. These services can include career counseling, skills training, career placement, post-employment support and workplace accommodation. However, the importance of VR extends beyond assisting individuals with disabilities in finding jobs. It plays a pivotal role in fostering a more inclusive and equitable society by helping to break down barriers that have historically excluded individuals with disabilities from the workforce.
According to the BLS' latest report, only 22.2% of Americans with disabilities are currently participating in the workforce, compared to 65.6% of individuals without a disability. Bridging this gap and creating new pathways for people with disabilities not only has the potential to transform an individual's life, but can also provide significant benefits to businesses and the U.S. economy as a whole.
If businesses actively participated in hiring individuals with disabilities, they would have access to a talent pool of millions of skilled, highly motivated workers. A 2023 Accenture study found that companies that actively embrace disability inclusion see nearly double the revenue and 2.6 times more net income. Researchers also found that these companies are 25% more likely to outperform in terms of productivity compared to their industry peers that don't prioritize inclusion.
Additionally, studies have shown that individuals with disabilities are great problem solvers and tend to have lower absenteeism rates. They also report high job satisfaction, which can lead to lower employee turnover and higher returns on investments in training and development.
The future of VR programs is being driven by technological advancements, changing societal attitudes and a deeper understanding of disability inclusion. To effectively tailor VR services to the unique needs, preferences and goals of each individual, many state agencies and businesses are exploring assistive technology and digital tools to provide greater accessibility. This includes the integration of AI into specialized software and other adaptive tools.
AI-powered tools can assist with job matching, skills assessment and personalized training. AI also has the potential to streamline case management processes, enhance client services and improve employment outcomes for people with disabilities. However, human oversight is still recommended to combat potential bias.
The rise of remote work opportunities has also opened new doors for individuals with disabilities, providing them with greater flexibility, accessibility and savings in commuting time and expenses. Building on the lessons learned from flexible work arrangements, state agencies have adjusted their VR services to offer training for individuals to learn digital skills, remote communication tools and effective strategies for working from home. I believe businesses can do the same.
VR plays a crucial role in fostering a more inclusive and economically vibrant society and workforce. VR programs can not only empower individuals with disabilities to secure meaningful employment, but they also provide them with valuable skills, resources and support to help them achieve financial independence. These services also unlock an untapped and highly motivated talent pool for businesses.
As technology and changing societal attitudes continue to reshape the employment landscape, it is crucial that we continue to invest in programs that eliminate barriers to employment, bridge the persistent employment gap and cultivate a society that acknowledges the unique potential of an individual with a disability.
Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
32 minutes ago
- The Hill
22 Palestinians killed in Gaza as Israeli forces fire on crowds at food aid sites, medics say
CAIRO (AP) — Israeli forces killed at least 22 people and wounded 20 others, many while attempting to get desperately needed food aid in southern Gaza on Monday, according to witnesses, hospitals, and Gaza's Health Ministry. Nasser Hospital in Khan Younis said it received the bodies of 11 people who were shot while returning from an aid site associated with Israeli and U.S.-backed Gaza Humanitarian Fund in southern Gaza, part of a deadly pattern that has killed more than 500 Palestinians in the chaotic and controversial aid distribution program over the past month. Ten others were killed at a United Nations aid warehouse in northern Gaza, according to the Health Ministry. The southern Gaza strike happened around 3 kilometers (1.8 miles) from the GHF site in the city of Khan Younis, as Palestinians returned from the site along one of the only accessible routes. Palestinians are often forced to travel long distances to access the GHF hubs in hopes of obtaining aid. Yousef Mahmoud Mokheimar was walking along with dozens others when he saw troops in vehicles and tanks racing toward them. At the beginning they fired warning shots in air, before firing at the crowds, he said. 'They fired at us indiscriminately,' he said, adding that he was shot in his leg, and a man was also shot while attempting to rescue him. He said he saw troops detaining six people, including three children, and it wasn't clear what happened to them. 'We don't know whether they are still alive,' he said. Monzer Hisham Ismail, another witness, said troops attacked the crowds while returning from the GHF hub in eastern Khan Younis. 'We were returning from the American aid hub … we were targeted by (the Israeli) artillery,' he said. Nasser Hospital said another person was killed near a GHF hub in the southern city of Rafah. The Israeli military said it was reviewing information about the attacks. In the past, the military has said it fires warning shots at people who move suspiciously or get too close to troops, including while collecting aid. Israel wants the GHF to replace a system coordinated by the United Nations and international aid groups. Along with the United States, Israel has accused the militant Hamas group of stealing aid and using it to prop up its rule in the enclave. The U.N. denies there is systematic diversion of aid. The Israeli military said it had recently taken steps to improve organization in the area, including the installation of new fencing, signage and the opening of additional routes to access aid. Israel says it only targets militants and blames civilian deaths on Hamas, accusing the militants of hiding among civilians because they operate in populated areas. In northern Gaza, at least 10 Palestinians were killed in an Israeli strike on an aid warehouse in Gaza City, according to the Health Ministry's ambulance and emergency service. It wasn't immediately clear whether there was aid at the warehouse. The strike in Gaza City came as the military intensified its bombardment campaign across the city and the nearby Jabaliya refugee camp. On Sunday and Monday, Israel issued widespread evacuation orders for large swaths of northern Gaza. Palestinians reported massive bombing overnight into Monday morning, describing the fresh attacks as a 'scorched earth' campaign that targeted mostly empty buildings and civilian infrastructure above the ground. 'They destroy whatever left standing … the sound of bombing hasn't stopped,' said Mohamed Mahdy, a Gaza City resident who fled his damaged house Monday morning. Fares Awad, head of the Health Ministry's emergency and ambulance services in northern Gaza, said that most of Gaza City and Jabaliya have become inaccessible and ambulances were unable to respond to distress calls from people trapped in the rubble. The Israeli military said it had taken multiple steps to notify civilians of operations to target Hamas' military command and control centers in northern Gaza. ___ Lidman reported from Tel Aviv, Israel. ___ Follow the AP's war coverage at
Travel Weekly
33 minutes ago
- Travel Weekly
Etihad CEO Antonoaldo Neves on strategy and its surprise move into Charlotte
After years of struggle before and after the pandemic, Abu Dhabi-based Etihad has returned to profitability and is growing substantially. Recently, the airline surprised nearly everyone by announcing it will begin Charlotte service next May. Airlines editor Robert Silk spoke about the decision with Etihad CEO Antonoaldo Neves at the IATA Annual General Meeting in New Delhi this month. Antonoaldo Neves Q: Why Charlotte? A: It's such a big, underserved market. There's no airline flying from the Middle East to Charlotte. There's a lot of immigration to the Carolinas today. We are really excited. We think it's a unique value proposition. Q: Your partner American dominates that airport. Clearly codeshare business will be key for you there, right? A: Every time we have interline and codeshare it does help. But we also have markets in the U.S. where customers on codeshares are less than 5%. I'm not going to name the cities. But in the U.S. it ranges from 5% to 25%. Charlotte may be 5%. We don't know. Q: I read that even Charlotte Airport didn't know you were going to fly there until a couple days before your public announcement. How come? There was speculation that you made the decision because Donald Trump was in the region at the time. A: We have a seven-year plan for our destinations. Charlotte was there for the past 3.5 years. Mr. Trump's visit to the United Arab Emirates was a good marketing opportunity for us. So, we could have announced in March next year. And that was the plan. But my team told me, "Why not anticipate?" In the end, if we get some news coverage because of this for free, why not? We were planning to start negotiations with Charlotte Airport by the end of this year. But we called them and said, "Look guys, we need to do this because we believe there is a marketing opportunity." That's business, right? We need to take all the opportunities that we have to market and sell tickets. Q: You launch Atlanta flights on July 2. And you started Boston last year. After your previous U.S. peak in 2017, you had dropped Los Angeles, Dallas and San Francisco. Once you add Charlotte, you'll be back to six U.S. routes. Tell us about your U.S. strategy. A: Because we have U.S. Customs Preclearance in Abu Dhabi, we are in the unique position to offer people in the Gulf Cooperation Council, India and Southeast Asia, and to Americans, an amazing experience. Think about Boston: Many of our customers connect beyond Boston with our partner JetBlue; you don't have to pick up your bag. We'll move to about 40 weekly frequencies to the U.S. next year. That's nothing. When I was at TAP Portugal, we had about 20 to 30 weekly frequencies to the U.S. Today, if I'm not mistaken, they have weekly 80. I believe Etihad can get there one day, but we need to do it differently. But I don't see any reason we can't double capacity to the U.S. in the next five years. Q: How many new destinations would you anticipate in those five years? A: Maybe three to five. Q: How do you position yourself within a market with stalwarts Emirates and Qatar Airways as well as ambitious potential rivals in Saudi Arabia, even India? A: We are proud of the work we have been doing. The average global net margin is 3%. Last year we did 6%. But we want more. I see Emirates doing 15%. Qatar doing 9%. I want to get 10%, 12%, 15%. I need to have muscle to fight downturns and competition in the future. The market is growing so much in the region that I believe there is space for everyone to make money. We grew 25% last year. If we have a stronger carrier, we can grow the pie, and at the same we can be ready to fight if the pie's not growing.
Miami Herald
34 minutes ago
- Miami Herald
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older CAMBRIDGE, MA / ACCESS Newswire / June 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive results from a Phase 3 efficacy study (P304) evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010, the Company's seasonal influenza (flu) vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older. mRNA-1010 achieved the most stringent superiority criterion prespecified in the protocol, with an rVE of 26.6% (95% CI; 16.7%, 35.4%) in the overall study population. Additionally, strong rVE was observed for each influenza strain contained in the vaccine, including A/H1N1 (rVE=29.6%), A/H3N2 (rVE=22.2%), and the B/Victoria lineages (rVE=29.1%). Subgroup analyses confirmed a consistently strong rVE point estimate across age groups, risk factors and previous influenza vaccination status. In participants aged 65 years and older, mRNA-1010 demonstrated an rVE of 27.4%. "Today's strong Phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in older adults. The severity of this past flu season underscores the need for more effective vaccines," said Stéphane Bancel, Chief Executive Officer of Moderna. "An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination vaccines." In a previous Phase 3 study, mRNA-1010 had already demonstrated superior seroconversion rates and geometric mean titer ratios (GMR) against all strains included in the vaccine compared to both high-dose and standard-dose licensed seasonal influenza vaccine. [1] According to the CDC, seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-2025 season. [2] More than 600,000 Americans were hospitalized due to flu-related illness last year, leading to substantial direct and indirect costs, as well as widespread disruption to daily life and work. [3] P304 ( NCT06602024 ) is a Phase 3, randomized, observer-blind, active-controlled, case-driven, pivotal efficacy, immunogenicity and safety study. The trial enrolled 40,805 adults aged 50 years and older across 11 countries. Participants were randomly assigned to receive either a single dose of mRNA-1010 or a standard-dose licensed comparator, with a median follow-up of six months. Safety and tolerability of mRNA-1010 were consistent with reported results from a previous Phase 3 study. [4] The majority of solicited adverse reactions (SARs) were mild. Injection site pain was the most common local SAR, and fatigue, headache and myalgia were the most common systemic SARs reported. There were no significant differences between the groups in the rates of unsolicited adverse events, serious adverse events, or adverse events of special interest. Moderna plans to present these data at an upcoming medical conference and submit for peer-reviewed publication. The Company will engage with regulators on filing submissions for mRNA-1010. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's engagement with regulators on filing submissions for its standalone flu vaccine candidate; and the efficacy, safety and tolerability of mRNA-1010. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at . Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media: Chris RidleyHead of Global Media Relations+1 Investors: Lavina TalukdarSenior Vice President & Head of Investor Relations+1 SOURCE: Moderna, Inc.
